2: Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. 2010
Add to clipboard

3: A Comparison of Venlafaxine and SSRIs in Deliberate Self-poisoning. 2010
Add to clipboard

4: Efficacy of Venlafaxine for Symptomatic Relief in Young Adult Patients With Functional Chest Pain: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. 2010
Add to clipboard

5: Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome. 2010
Add to clipboard

6: Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. 2010
Add to clipboard

7: Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. 2010
Add to clipboard

8: Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine. 2010
Add to clipboard

9: Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. 2010
Add to clipboard

10: Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. 2010
Add to clipboard

11: Chronic effects of venlafaxine on synaptophysin and neuronal cell adhesion molecule in the hippocampus of cerebral ischemic mice. 2010
Add to clipboard

12: Serotonin Transporter Gene Polymorphism Associated with Short-Term Treatment Response to Venlafaxine. 2010
Add to clipboard

13: Antidepressant-Like Effect of Venlafaxine Is Abolished in mu-Opioid Receptor-Knockout Mice. 2010
Add to clipboard

14: Venlafaxine-Associated Serotonin Syndrome Causing Severe Rhabdomyolysis and Acute Renal Failure in a Patient With Idiopathic Parkinson Disease. 2010
Add to clipboard

15: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. 2010
Add to clipboard

16: Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: A single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states. 2010
Add to clipboard

17: Comparison of the effectiveness of venlafaxine in peri- and postmenopausal patients with major depressive disorder. 2010
Add to clipboard

18: Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. 2009
Add to clipboard

19: The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. 2009
Add to clipboard

20: Venlafaxine-induced gynecomastia in a young patient: a case report. 2009
Add to clipboard

21: Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. 2009
Add to clipboard

22: Is the antidepressant venlafaxine effective for the treatment of functional dyspepsia? 2009
Add to clipboard

23: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. 2009
Add to clipboard

24: Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis? 2009
Add to clipboard

25: Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. 2009
Add to clipboard

26: The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. 2009
Add to clipboard

27: Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. 2009
Add to clipboard

28: Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. 2009
Add to clipboard

29: Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. 2009
Add to clipboard

30: A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. 2009
Add to clipboard

31: Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. 2009
Add to clipboard

32: Cognitive Deterioration after Venlafaxine Overdose. 2009
Add to clipboard

33: Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. 2009
Add to clipboard

34: Pro-inflammatory biomakers in depression: treatment with venlafaxine. 2009
Add to clipboard

35: Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. 2009
Add to clipboard

36: Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. 2009
Add to clipboard

37: [Milnacipran and venlafaxine at flexible doses (up to 200mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomised, double blind exploratory study.] 2009
Add to clipboard

38: Venlafaxine-induced psychotic symptoms. 2009
Add to clipboard

39: Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. 2008
Add to clipboard

40: A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. 2008
Add to clipboard

41: Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. 2008
Add to clipboard

42: [Palinopsia following discontinuation of venlafaxine] 2008
Add to clipboard

43: Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. 2008
Add to clipboard

44: An open-label trial of venlafaxine in body dysmorphic disorder. 2008
Add to clipboard

45: Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. 2008
Add to clipboard

46: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. 2008
Add to clipboard

47: Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine. 2008
Add to clipboard

48: Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. 2008
Add to clipboard

49: A fatal case of venlafaxine overdose. 2008
Add to clipboard

50: Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial. 2008
Add to clipboard

51: Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. 2008
Add to clipboard

52: Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. 2008
Add to clipboard

53: Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. 2008
Add to clipboard

54: Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. 2008
Add to clipboard

55: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. 2008
Add to clipboard

56: The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. 2008
Add to clipboard

57: Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret. 2008
Add to clipboard

58: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. 2008
Add to clipboard

59: Stimulus properties of venlafaxine in a conditioned taste aversion procedure. 2008
Add to clipboard

60: The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation. 2008
Add to clipboard

61: Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. 2008
Add to clipboard

62: [Hypersensitivity pneumonitis due to venlafaxine] 2008
Add to clipboard

63: Pro-inflammatory biomakers in depression: Treatment with venlafaxine. 2008
Add to clipboard

64: A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. 2007
Add to clipboard

65: Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. 2007
Add to clipboard

66: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. 2007
Add to clipboard

67: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. 2007
Add to clipboard

68: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. 2007
Add to clipboard

69: Syndrome of inappropriate secretion of antidiuretic hormone due to citalopram and venlafaxine. 2007
Add to clipboard

70: Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. 2007
Add to clipboard

71: Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. 2007
Add to clipboard

72: Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. 2007
Add to clipboard

73: Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. 2007
Add to clipboard

74: Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. 2007
Add to clipboard

75: Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. 2007
Add to clipboard

76: Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection. 2007
Add to clipboard

77: Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. 2007
Add to clipboard

78: The effects of venlafaxine on autonomic functions in healthy volunteers. 2007
Add to clipboard

79: Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. 2007
Add to clipboard

80: Venlafaxine in the treatment of panic disorder. 2007
Add to clipboard

81: Chronic administration of venlafaxine fails to attenuate 5-HT1A receptor function at the level of receptor-G protein interaction. 2006
Add to clipboard

82: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. 2006
Add to clipboard

83: Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study. 2006
Add to clipboard

84: Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder. 2006
Add to clipboard

85: (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. 2006
Add to clipboard

86: Treatment of anxiety disorders with venlafaxine XR. 2006
Add to clipboard

87: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 2006
Add to clipboard

88: Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. 2006
Add to clipboard

89: Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine. 2006
Add to clipboard

90: Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. 2006
Add to clipboard

91: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. 2006
Add to clipboard

92: [Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder] 2006
Add to clipboard

93: [Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review] 2006
Add to clipboard

94: Effects of venlafaxine and desipramine on heroin-induced conditioned place preference in the rat. 2006
Add to clipboard

95: Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. 2006
Add to clipboard

96: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. 2006
Add to clipboard

97: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. 2006
Add to clipboard

98: Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. 2006
Add to clipboard

99: Neonatal seizures from in utero venlafaxine exposure. 2006
Add to clipboard

100: A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. 2006
Add to clipboard

101: The role of venlafaxine in the treatment of obsessive-compulsive disorder. 2005
Add to clipboard

102: Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. 2005
Add to clipboard

103: Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. 2005
Add to clipboard

104: Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. 2005
Add to clipboard

105: Remission from depression : a review of venlafaxine clinical and economic evidence. 2005
Add to clipboard

106: Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. 2005
Add to clipboard

107: Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. 2005
Add to clipboard

108: The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. 2005
Add to clipboard

109: Effects of paroxetine and venlafaxine XR on heart rate variability in depression. 2005
Add to clipboard

110: [Trazodone and venlafaxine in treatment of depressive disorders] 2005
Add to clipboard

111: Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. 2005
Add to clipboard

112: Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. 2005
Add to clipboard

113: Venlafaxine-induced urinary incontinence resolved after switching to sertraline. 2005
Add to clipboard

114: Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. 2005
Add to clipboard

115: The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. 2005
Add to clipboard

116: Venlafaxine and bladder function. 2005
Add to clipboard

117: Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression--evolution of antidepressants and the role of the"neuro-immune"system. 2005
Add to clipboard

118: Venlafaxine and serious withdrawal symptoms: warning to drivers. 2005
Add to clipboard

119: The treatment of depression with different formulations of venlafaxine: a comparative analysis. 2004
Add to clipboard

120: A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. 2004
Add to clipboard

121: Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. 2004
Add to clipboard

122: Blockade of supraspinal 5-HT1A receptors potentiates the inhibitory effect of venlafaxine on wind-up activity in mononeuropathic rats. 2004
Add to clipboard

123: Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. 2004
Add to clipboard

124: Tolerability of high-dose venlafaxine in depressed patients. 2004
Add to clipboard

125: A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. 2004
Add to clipboard

126: Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. 2004
Add to clipboard

127: The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. 2004
Add to clipboard

128: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. 2004
Add to clipboard

129: Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. 2004
Add to clipboard

130: An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. 2004
Add to clipboard

131: S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. 2004
Add to clipboard

132: Effects of venlafaxine on ethanol withdrawal syndrome in rats. 2004
Add to clipboard

133: The response of synaptophysin and microtubule-associated protein 1 to restraint stress in rat hippocampus and its modulation by venlafaxine. 2004
Add to clipboard

134: Venlafaxine in the treatment of anxiety disorders. 2004
Add to clipboard

135: Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. 2003
Add to clipboard

136: Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. 2003
Add to clipboard

137: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. 2003
Add to clipboard

138: Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. 2003
Add to clipboard

139: The antihyperalgesic effect of venlafaxine in diabetic rats does not involve the opioid system. 2003
Add to clipboard

140: Shock-like sensations during venlafaxine withdrawal. 2003
Add to clipboard

141: The effects of venlafaxine on the subjective, reinforcing, and cardiovascular effects of cocaine in opioid-dependent and non-opioid-dependent humans. 2003
Add to clipboard

142: Venlafaxine in treatment-resistant obsessive-compulsive disorder. 2003
Add to clipboard

143: [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy] 2003
Add to clipboard

144: Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. 2003
Add to clipboard

145: Effects of venlafaxine on extracellular 5-HT, dopamine and noradrenaline in the hippocampus and on peripheral hormone concentrations in the rat in vivo. 2003
Add to clipboard

146: Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. 2003
Add to clipboard

147: Venlafaxine: a 2003 update. 2003
Add to clipboard

148: Venlafaxine treatment of fibromyalgia. 2003
Add to clipboard

149: Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. 2003
Add to clipboard

150: A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. 2003
Add to clipboard

151: Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. 2003
Add to clipboard

152: A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. 2003
Add to clipboard

153: Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. 2002
Add to clipboard

154: Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. 2002
Add to clipboard

155: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. 2002
Add to clipboard

156: Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety. 2002
Add to clipboard

157: Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142. 2002
Add to clipboard

158: [Delirium during withdrawal of venlafaxine] 2002
Add to clipboard

159: Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. 2002
Add to clipboard

160: Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. 2002
Add to clipboard

161: Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. 2002
Add to clipboard

162: Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. 2002
Add to clipboard

163: Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. 2002
Add to clipboard

164: Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. 2002
Add to clipboard

165: Review: venlafaxine is more effective than selective serotonin-reuptake inhibitors for depression. 2002
Add to clipboard

166: Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. 2002
Add to clipboard

167: Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. 2002
Add to clipboard

168: Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. 2002
Add to clipboard

169: Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. 2002
Add to clipboard

170: Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo. 2002
Add to clipboard

171: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. 2001
Add to clipboard

172: Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. 2001
Add to clipboard

173: Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. 2001
Add to clipboard

174: Treatment of neuropathic pain with venlafaxine. 2001
Add to clipboard

175: Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. 2001
Add to clipboard

176: S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. 2001
Add to clipboard

177: S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. 2001
Add to clipboard

178: Postmortem tissue concentrations of venlafaxine. 2001
Add to clipboard

179: Venlafaxine extended-release: a review of its use in the management of major depression. 2001
Add to clipboard

180: Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications. 2001
Add to clipboard

181: The pharmacoeconomics of venlafaxine in depression. 2001
Add to clipboard

182: Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. 2001
Add to clipboard

183: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. 2001
Add to clipboard

184: Venlafaxine in the treatment of premenstrual dysphoric disorder. 2001
Add to clipboard

185: A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. 2001
Add to clipboard

186: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. 2001
Add to clipboard

187: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. 2001
Add to clipboard

188: Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. 2000
Add to clipboard

189: Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. 2000
Add to clipboard

190: [Venlafaxine withdrawal syndrome: report of six cases and review of the literature] 2000
Add to clipboard

191: Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. 2000
Add to clipboard

192: Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. 2000
Add to clipboard

193: Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat. 2000
Add to clipboard

194: Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. 2000
Add to clipboard

195: Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine. 2000
Add to clipboard

196: Venlafaxine and its interaction with WAY 100635: effects on serotonergic unit activity and behavior in cats. 2000
Add to clipboard

197: Venlafaxine and treatment-resistant depression. 2000
Add to clipboard

198: Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. 2000
Add to clipboard

199: Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. 1999
Add to clipboard

200: O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. 1999
Add to clipboard

201: Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. 1999
Add to clipboard

202: Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. 1999
Add to clipboard

203: Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. 1999
Add to clipboard

204: Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. 1999
Add to clipboard

205: [Two new antidepressants: mirtazapine and venlafaxine] 1999
Add to clipboard

206: Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. 1999
Add to clipboard

207: [Psychopharmacological profile of venlafaxine] 1999
Add to clipboard

208: Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. 1999
Add to clipboard

209: Effect of venlafaxine hydrochloride in different preparations of isolated guinea-pig and rat organ tissues. 1999
Add to clipboard

210: Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. 1999
Add to clipboard

211: An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms. 1999
Add to clipboard

212: Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. 1999
Add to clipboard

213: Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression. 1999
Add to clipboard

214: Venlafaxine in the treatment of dysthymia: an open-label study. 1999
Add to clipboard

215: Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. 1999
Add to clipboard

216: Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose. 1999
Add to clipboard

217: Hyponatremia with venlafaxine. 1998
Add to clipboard

218: A meta-analysis of the effects of venlafaxine on anxiety associated with depression. 1998
Add to clipboard

219: [Pharma-Clinics. The drug of the month. Venlafaxine (Efexor)] 1998
Add to clipboard

220: New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. 1998
Add to clipboard

221: Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. 1998
Add to clipboard

222: Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. 1998
Add to clipboard

223: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. 1998
Add to clipboard

224: Lithium augmentation of venlafaxine in adolescent major depression. 1998
Add to clipboard

225: Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. 1998
Add to clipboard

226: Lack of beta adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. 1998
Add to clipboard

227: Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. 1998
Add to clipboard

228: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. 1998
Add to clipboard

229: Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia. 1998
Add to clipboard

230: [Prophylaxis of migraine: open study with venlafaxine in 42 patients] 1998
Add to clipboard

231: Effect of venlafaxine on pineal melatonin and noradrenaline in the male rat. 1998
Add to clipboard

232: Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. 1998
Add to clipboard

233: Venlafaxine: new preparation. Just another antidepressant. 1998
Add to clipboard

234: Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. 1997
Add to clipboard

235: Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. 1997
Add to clipboard

236: Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. 1997
Add to clipboard

237: Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. 1997
Add to clipboard

238: Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. 1997
Add to clipboard

239: Venlafaxine:a novel antidepressant compound. 1997
Add to clipboard

240: A review of the efficacy and tolerability of venlafaxine. 1997
Add to clipboard

241: Therapeutic options for treating major depression, and the role of venlafaxine. 1996
Add to clipboard

242: Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring. 1996
Add to clipboard

243: Antidepressant options: venlafaxine in perspective. 1996
Add to clipboard

244: Dose-response relationship with venlafaxine. 1996
Add to clipboard

245: The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. 1996
Add to clipboard

246: Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression. 1996
Add to clipboard

247: Venlafaxine oxidation in vitro is catalysed by CYP2D6. 1996
Add to clipboard

248: Serotonin syndrome from venlafaxine-tranylcypromine interaction. 1996
Add to clipboard

249: Distribution of venlafaxine in three postmortem cases. 1996
Add to clipboard

250: Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. 1996
Add to clipboard

251: Venlafaxine: a novel antidepressant that has a dual mechanism of action. 1996
Add to clipboard

252: Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. 1996
Add to clipboard

253: Venlafaxine: measuring the onset of antidepressant action. 1995
Add to clipboard

254: Nefazodone and venlafaxine: two new agents for the treatment of depression. 1995
Add to clipboard

255: Rapid onset of action of venlafaxine. 1995
Add to clipboard

256: Clinical utility of venlafaxine in comparison with other antidepressants. 1995
Add to clipboard

257: A case report of venlafaxine toxicity. 1995
Add to clipboard

258: Venlafaxine: a structurally unique and novel antidepressant. 1995
Add to clipboard

259: Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. 1995
Add to clipboard

260: Venlafaxine treatment of panic disorder: a case series. 1995
Add to clipboard

261: Venlafaxine. A review of its pharmacology and therapeutic potential in depression. 1995
Add to clipboard

262: Cardiovascular safety in depressed patients: focus on venlafaxine. 1995
Add to clipboard

263: Venlafaxine in social phobia. 1995
Add to clipboard

264: Venlafaxine in the treatment of borderline personality disorder. 1995
Add to clipboard

265: Venlafaxine: a heterocyclic antidepressant. 1994
Add to clipboard

266: The role of venlafaxine in rational antidepressant therapy. 1994
Add to clipboard

267: Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjects. 1993
Add to clipboard

268: Placebo-controlled trial of venlafaxine for the treatment of major depression. 1991
Add to clipboard